Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05343143 · ClinicalTrials.gov registry record · NA
NeuraGen 3D Pilot Study
A NA study, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT05343143: Clinical Trial NA study, sponsored by Integra LifeSciences Corporation.
NCT05343143 is a NA study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05343143, a NA study, was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a 10-subject, 12-month follow-up, prospective, multi-center, open-label, single arm clinical trial designed to understand the initial performance characteristics and confirm the safety profile of the NeuraGen 3D Nerve Guide Matrix.
Primary Outcome
To be assessed during in office visits using the DeMayo 2-point discrimination device
Interventions
- DEVICE NeuraGen 3D Nerve Guide Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-05-15 |
| Est. Completion | 2024-05-13 |
| Phase | NA |
Why NCT05343143 stopped before completion
NCT05343143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which NeuraGen 3D Nerve Guide Matrix is the first listed.
NCT05343143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05343143 about?
NCT05343143 is a clinical study titled "NeuraGen 3D Pilot Study". This is a 10-subject, 12-month follow-up, prospective, multi-center, open-label, single arm clinical trial designed to understand the initial performance characteristics and confirm the safety profile of the NeuraGen 3D Nerve Guide Matrix.
What is the current status of trial NCT05343143?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2022-05-15. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT05343143?
The interventions under investigation include: NeuraGen 3D Nerve Guide Matrix (DEVICE).
Who is sponsoring clinical trial NCT05343143?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05343143's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI